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1. INTRODUCTION {#cam41962-sec-0005}
===============

Breast cancer is reported as the most widespread tumor in women.[1](#cam41962-bib-0001){ref-type="ref"}, [2](#cam41962-bib-0002){ref-type="ref"} It is universally accepted that the adjuvant or neoadjuvant systemic therapy substantially improves the survival probability in patients with breast cancer.[3](#cam41962-bib-0003){ref-type="ref"}, [4](#cam41962-bib-0004){ref-type="ref"}, [5](#cam41962-bib-0005){ref-type="ref"}, [6](#cam41962-bib-0006){ref-type="ref"} Traditionally, the clinicopathological risk features such as age,[7](#cam41962-bib-0007){ref-type="ref"} tumor size,[8](#cam41962-bib-0008){ref-type="ref"} histologic type,[9](#cam41962-bib-0009){ref-type="ref"} status of axillary lymph nodes,[10](#cam41962-bib-0010){ref-type="ref"} and hormone‐receptor[11](#cam41962-bib-0011){ref-type="ref"}, [12](#cam41962-bib-0012){ref-type="ref"} could divide patients into high‐ and low‐risk subgroup, but they have limited predictive power. Then, many biomarkers are explored for predicting the prognosis of breast cancer, but they could not still satisfy clinical practice.[13](#cam41962-bib-0013){ref-type="ref"}, [14](#cam41962-bib-0014){ref-type="ref"}, [15](#cam41962-bib-0015){ref-type="ref"} Thus, it is urgently to investigate some new biomarkers to add the diagnostic power to the current predictive system.

Previous studies showed that the inflammatory microenvironment as the seventh hallmark of cancer could be activated to promote tumor process.[16](#cam41962-bib-0016){ref-type="ref"} Zhao et al discovered that three inflammatory genes (*IL‐6*, *IL‐1A,* and *CSF3*) could predict prognosis of patients with diffuse large B‐cell lymphoma,[17](#cam41962-bib-0017){ref-type="ref"} and the inflammation‐related gene *TBX21* could evaluate the survival of patients and increase cancer stemness via the TBX21‐IL‐4 pathway in lung adenocarcinoma.[18](#cam41962-bib-0018){ref-type="ref"} Loza et al summarized that the pathway comprised of inflammation genes could define genetic risk factors for cancers.[19](#cam41962-bib-0019){ref-type="ref"} Currently, there is no data regarding a reliable model including some inflammatory genes to predict prognosis of patients with breast cancer.

To address this knowledge gap, we develop a three‐mRNA model including three inflammation‐related genes with the Cox regression method to evaluate prognosis independently and predict survival probability precisely in breast cancer patients with or without metastasis from The Cancer Genome Atlas (TCGA). Then, we validated the generalization ability of this model in another four independent cohorts from Gene Expression Omnibus (GEO) datasets. And we also compared its diagnostic power to single mRNAs and clinicopathological risk factors.

2. METHODS {#cam41962-sec-0006}
==========

2.1. Patients and samples {#cam41962-sec-0007}
-------------------------

The clinical materials and mRNA data were collected from a research team (Cat. \#BR1504a, Shanxi, Alenabio company, China), The Cancer Genome Atlas (TCGA) ([https://cancergenome.nih.gov](://cancergenome.nih.gov)), and GEO datasets ([https://www.ncbi.nlm.nih.gov/gds](://www.ncbi.nlm.nih.gov/gds)). After the removal of missing values, a total of 1938 breast cancer patients and 25 normal samples were applied into in this study, including 140 patients and 10 normal samples from Alenabio company, 1095 patients from TCGA, 249 patients from GSE21653, 237 patients from GSE4922, 138 patients from GSE22226, 79 patients from GSE58812, and 15 normal controls from GSE8977 separately. The normalization of expression values in studied genes was completed with a house‐keeping gene GAPDH. The formalin‐fixed paraffin‐embedded (FFPE) specimens of the 140 patients and 10 normal controls were collected between 2003 and 2006 and pathologically confirmed by the pathologist in the Nankai University.

2.2. Screening process of the significant genes {#cam41962-sec-0008}
-----------------------------------------------

A total of 156 candidate genes were screened from these 1027 inflammation‐related genes by a medium throughput RNAi screen platform.[20](#cam41962-bib-0020){ref-type="ref"} And then, 14 significant genes were collected from these 156 primary screening genes in breast cancers between with and without metastasis (*P* \< 0.15, *t* test method, Table [S1](#cam41962-sup-0006){ref-type="supplementary-material"}). Finally, the three significant genes (TBX21, TGIF2, and CYCS) were obtained from above genes among the metastatic, relapse and tumorigenesis group when *P* \< 0.15 in 2 of 3 compared groups with *t* test method, which were on behalf of the clinical characteristics of the cancer stemness.

2.3. Bio‐experiment methods {#cam41962-sec-0009}
---------------------------

The biology experiment methods applied into this study including cell culture, real‐time PCR, Western blotting, and immunohistochemistry were similar with the research methods as described previously.[18](#cam41962-bib-0018){ref-type="ref"}, [20](#cam41962-bib-0020){ref-type="ref"} Primers used for the experiments are summarized in Table [S2](#cam41962-sup-0007){ref-type="supplementary-material"}.

2.4. Functional enrichment analysis {#cam41962-sec-0010}
-----------------------------------

The bioinformatical analysis methods were analogous with our research methods as described previously.[18](#cam41962-bib-0018){ref-type="ref"} Meanwhile, we applied the STRING tool ([https://string-db.org/](://string-db.org/)) to perform the functional protein association networks.

2.5. Statistical analysis {#cam41962-sec-0011}
-------------------------

We defined a median as the cutoff value in the expression of the studied genes in each set. And Pearson\'s chi‐square test method was applied to analyze the statistical significance in the basic characteristics.[21](#cam41962-bib-0021){ref-type="ref"} The *t* test was performed to distinguish the distributive difference of the studied genes' expression between cancers and healthy samples or between the high‐ and low‐risk groups. The correlation analysis between two genes in this signature was measured with Spearman correlation analysis in the TCGA set. In the overall survival (OS) analyses, Random Survival Forest (RSF) algorithm and Cox proportional hazards regression analysis were used to screen the optimal method to construct the prognostic model. Next, the Kaplan‐Meier method was used to analyze the relationship between factors and overall survival, and the log‐rank test to compare survival curves. The Cox regression model was selected to complete the multivariate survival analysis and data stratification analysis for exploring the independency of this signature model.[22](#cam41962-bib-0022){ref-type="ref"} Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed in each dataset. The prognostic performance at 3, 5, and 10 years was evaluated by time‐dependent ROC curves. The Cox regression coefficients were to generate nomograms, and bootstrap cross‐validation method was selected to prove their predictive accuracy. Meanwhile, we used calibration to assess whether the actual results approximate the predicted outcomes for each nomogram. The nomogram and calibration plots were performed with *rms* R package, and the other statistical tests were conducted with R software (version 3.4.4). *P* \< 0.05 was defined as the significant threshold in statistical results.

3. RESULTS {#cam41962-sec-0012}
==========

3.1. Identification and derivation of a three‐mRNA model in predicting prognosis for patients with breast cancer {#cam41962-sec-0013}
----------------------------------------------------------------------------------------------------------------

To develop a predictive model, we compared the expression values of 1027 inflammation‐related genes[18](#cam41962-bib-0018){ref-type="ref"}, [19](#cam41962-bib-0019){ref-type="ref"} and obtained three significant mRNAs (*TBX21*, *TGIF2,* and *CYCS*) between 669 breast cancer patients from TCGA and 15 normal controls from GSE8977 (*P* \< 0.05; Figure [1](#cam41962-fig-0001){ref-type="fig"}A). In line with above, the expression patterns of these three genes were verified in 7 cell lines (Figure [S1](#cam41962-sup-0001){ref-type="supplementary-material"}A‐C) and 150 tissues from normal (n = 10) and cancer (n = 140) samples (Figure [S1](#cam41962-sup-0001){ref-type="supplementary-material"}D‐F). Then, we discovered that the mortality was negatively correlated with the expression value of *TBX21*and *TGIF2*, but positively with *CYCS* in training set (n = 1095, Figure [1](#cam41962-fig-0001){ref-type="fig"}B). With no multicollinearity (Spearman\'s r ≤ 0.15; Figure [S2](#cam41962-sup-0002){ref-type="supplementary-material"}A), these genes were necessary for this new model by RSF analysis (depth ≥ 0.5; Figure [S2](#cam41962-sup-0002){ref-type="supplementary-material"}B). Considering a balance between the discriminant error rate and the number of mRNAs (Figure [S2](#cam41962-sup-0002){ref-type="supplementary-material"}C), we finally integrated three mRNAs into a predictive model with Cox regression algorithm: Risk scores = −0.082\**TBX21*‐ 0.05\**TGIF2*+ 0.069\**CYCS*. With a cutoff point defined by the median value[17](#cam41962-bib-0017){ref-type="ref"}, [18](#cam41962-bib-0018){ref-type="ref"}, [22](#cam41962-bib-0022){ref-type="ref"} (0.020, Figure [1](#cam41962-fig-0001){ref-type="fig"}C,D), patients with high‐risk scores (risk score\>0.020) were classified into high‐risk group. In contrast, the patients with risk score ≥0.020 were divided into low‐risk group. The basal characteristics (Table [1](#cam41962-tbl-0001){ref-type="table"}) were not significantly different between the low‐ and high‐risk groups except for race (*P* = 0.014), tumor stage (*P* = 0.010), copy number aberration (CNA, *P* = 0.040), surgical margin status (*P* \< 0.0001), and menopause status (*P* = 0.014).

![The model construction. A, Different expression of three significant mRNAs between breast cancers and normal controls (\**P* \< 0.05, *t* test method). B, Scatter plot shows three mRNA expression values to dead as a first event for those in whom this occurred (yellow dots), and alive for all other patients (gray dots). Shafts on the x‐axis represent breast cancer patients. Red spline and dotted line represent the fitted trend and the overall trend of mortality for patients, respectively. C, Three‐dimensional stereogram shows three‐mRNA‐based classifier stratifies patients into high (red dots)‐ and low (black dots)‐risk group with median as a cutoff value. D, Histogram shows three‐mRNA‐based classifier divides patients into high (red color)‐ and low (black color)‐risk group with median of predictive scores as a cutoff value](CAM4-8-593-g001){#cam41962-fig-0001}

###### 

Baseline characteristics of patients by 3‐mRNA signature in TCGA dataset

                           Number of patients   Low risk (%)   High risk (%)   *P*‐value
  ------------------------ -------------------- -------------- --------------- -----------
  Gender                                                                       
  Male                     10                   7 (70)         3 (30)          0.527
  Female                   990                  558 (56)       432 (44)        
  Age                                                                          
  ≤60                      553                  300 (54)       253 (46)        0.110
  \>60                     447                  265 (59)       182 (41)        
  Race                                                                         
  White                    718                  391 (54)       327 (46)        0.014
  Nonwhite                 187                  83 (44)        104 (56)        
  ER status                                                                    
  Negative                 237                  123 (52)       114 (48)        0.073
  Positive                 804                  470 (58)       334 (42)        
  PR status                                                                    
  Negative                 342                  201 (59)       141 (41)        0.424
  Positive                 698                  392 (56)       306 (44)        
  HER2 status                                                                  
  Negative                 557                  321 (58)       236 (42)        0.223
  Positive                 355                  190 (54)       165 (46)        
  Tumor stage                                                                  
  ≤II                      847                  464 (55)       383 (45)        0.010
  \>II                     153                  101 (66)       52 (34)         
  Lymph node stage                                                             
  0                        471                  271 (58)       200 (42)        0.533
  ≥1                       529                  294 (56)       235 (44)        
  Metastasis status                                                            
  Yes                      428                  228 (53)       200 (47)        0.475
  No                       667                  370 (55)       297 (45)        
  CNA                                                                          
  ≤0.251                   539                  275 (51)       264 (49)        0.040
  \>0.251                  538                  308 (57)       230 (43)        
  Surgical margin status                                                       
  Positive                 102                  87 (85)        15 (15)         \<0.0001
  Negative                 844                  468 (55)       376 (45)        
  Mutation count                                                               
  ≤30                      489                  269 (55)       220 (45)        0.252
  \>30                     486                  285 (59)       201 (41)        
  Neoadjuvant therapy                                                          
  Yes                      11                   9 (82)         2 (18)          0.088
  No                       988                  555 (56)       433 (44)        
  Tumor location                                                               
  Left                     523                  298 (57)       225 (43)        0.749
  Right                    477                  267 (56)       210 (44)        
  Clinical stage                                                               
  ≤II                      761                  419 (55)       342 (45)        0.088
  \>II                     238                  146 (61)       92 (39)         
  Menopause status                                                             
  ≤12 mo since LMP         280                  179 (64)       101 (36)        0.014
  \>12 mo since LMP        646                  357 (55)       289 (45)        
  Neoplasm status                                                              
  Tumor‐free               772                  421 (55)       351 (45)        0.893
  With tumor               80                   43 (54)        37 (46)         

TCGA, The Cancer Genome Atlas.

John Wiley & Sons, Ltd

3.2. The three‐mRNA model predicted the prognosis effectively in a training set and 4 independent testing sets {#cam41962-sec-0014}
--------------------------------------------------------------------------------------------------------------

Applying this new model into clinical practice, we found that the mRNA expression of *TBX21* and *TGIF2* in breast cancer patients with high‐risk value was significantly lower than those with low‐risk value (*P \< *0.0001), but inversely for *CYCS*. The 5‐year OS rates were 79.1% (74.4%‐84.0%) for all patients, 84.5% (78.8%‐90.5%) in the low‐risk group (n = 598), and 73.1% (65.9%‐81.2%) in high‐risk group (n = 497), respectively (HR = 1.573 (1.090‐2.271), *P* = 0.016; Figure [2](#cam41962-fig-0002){ref-type="fig"}A). These results pointed out that this model could discriminate breast cancer patients with high or low risk of survival.

![Risk stratification by the model, and overall survival analysis by Kaplan‐Meier method in the whole patients and between high‐ and low‐risk group. A, training cohort. B‐E, independent testing cohorts. CI, confidence interval; HR, hazard ratio](CAM4-8-593-g002){#cam41962-fig-0002}

To validate the generalization of this new model, a total of 703 breast cancer patients were classified into low and high subgroups with the same cutoff point in another 4 independent testing sets (GSE21653, GSE4922, GSE22226, and GSE58812). The 5‐year OS rates were 67.7% (61.6%‐74.3%) for all patients (n = 249), 73.1% (66.0%‐81.0%) in low‐risk group (n = 154) and 58.2% (47.9%‐70.7%) in high‐risk group (n = 95), respectively, in GSE21653 (HR = 1.630 (1.022‐2.598), *P* = 0.040; Figure [2](#cam41962-fig-0002){ref-type="fig"}B). For the other three testing sets, the 5‐year OS rates were analogous with the result above in all patients, high‐ and low‐risk group (Figure [2](#cam41962-fig-0002){ref-type="fig"}C‐E). Therefore, these results indicated that the three‐mRNA model was powerful to identify the prognosis of breast cancer patients with luminal, Her2+, or basal‐like subtype.

3.3. Prognostic prediction by the three‐mRNA model was independent of clinicopathological factors {#cam41962-sec-0015}
-------------------------------------------------------------------------------------------------

To assess the independence of this model in predicting prognosis, we performed multivariate Cox regression analysis and discovered this model significantly associated with survival when adjusted for the other 14 clinical variables in TCGA set, as well as age, CNA, and neoplasm status (HR = 1.843 (1.094‐3.104), *P* = 0.022; Table [2](#cam41962-tbl-0002){ref-type="table"}). Next, data stratification analysis was completed between age, CNA, or neoplasm status. All patients were divided into young group (≤ 60 years, n = 553) and older group (\>60 years, n = 447). As shown in Figure [3](#cam41962-fig-0003){ref-type="fig"}A, the cutoff value of the model could subclassify young patients into high‐ and low‐risk group with significant prognosis (HR = 3.098 (1.677‐5.722), *P* = 0.0003). The 5‐year OS rates of patients with high‐risk scores were 71.3% (95% CI: 58.5‐86.9), which was also significantly decreased compared with patients with low‐risk scores whose corresponding proportions were 89.0% (83.6‐94.7). For the older group, the model exposed the comparable prognostic power (*P* = 0.0029; Figure [3](#cam41962-fig-0003){ref-type="fig"}B). Subsequently, the model was further measured in patients with different CNA or neoplasm status. The patients from each subgroup were subclassified into high‐ and low‐risk group with dramatically different prognosis (*P* \< 0.05). The 5‐year OS rates of patients with high‐risk scores were notably worse than those with low‐risk scores (74.4% vs 90.9% in less CNA group (≤ 0.251; *P* = 0.028; Figure [3](#cam41962-fig-0003){ref-type="fig"}C) and 81.4% vs 93.2% in tumor‐free group (*P* = 0.002; Figure [3](#cam41962-fig-0003){ref-type="fig"}E); median survival time (months): 67.4 vs 129.0 in more CNA group (\>0.251; *P* = 0.0008; Figure [3](#cam41962-fig-0003){ref-type="fig"}D) and 55.0 vs 83.8 in with tumor group (*P* = 0.039; Figure [3](#cam41962-fig-0003){ref-type="fig"}F)). These results demonstrated that the prognostic power of the new model is independent of other clinicopathological characteristics for breast cancer patients.

###### 

Univariate and multivariate Cox regression analysis of the three‐mRNA‐based classifier in TCGA set

  Factors                                            Univariate analysis     Multivariate analysis                          
  -------------------------------------------------- ----------------------- ----------------------- ---------------------- -------
  Three‐mRNA‐based classifier (High risk/Low risk)   2.438 (1.684‐3.532)     0.000                   1.843 (1.094‐3.104)    0.022
  Gender (Male/Female)                               0.049 (0.000‐792.724)   0.542                                          
  Age (\>60/≤60)                                     1.793 (1.248‐2.577)     0.002                   2.872 (1.597‐5.167)    0.000
  Race (White/Nonwhite)                              1.086 (0.676‐1.746)     0.733                                          
  ER status (Positive/Negative)                      0.777 (0.516 ‐ 1.172)   0.229                                          
  PR status (Positive/Negative)                      0.692 (0.472 ‐ 1.014)   0.059                                          
  HER2 status (Positive/Negative)                    1.106 (0.676 ‐ 1.810)   0.687                                          
  Tumor stage (\>II/≤II)                             1.187 (0.768‐1.835)     0.440                                          
  Lymph node stage (≥1/0)                            2.524 (1.687‐3.776)     0.000                   1.161 (0.622‐2.167)    0.638
  Metastasis status (Yes/No)                         1.595 (1.109‐2.296)     0.012                   1.503 (0.936‐2.415)    0.092
  CNA (\>0.251/≤0.251)                               1.781 (1.224‐2.592)     0.003                   2.043 (1.229‐3.396)    0.006
  Surgical margin status (Positive/Negative)         1.357 (0.802‐2.296)     0.255                                          
  Mutation count (\>30/≤30)                          1.118 (0.771‐1.621)     0.555                                          
  Neoadjuvant therapy (Yes/No)                       4.985 (1.560‐15.927)    0.007                   3.033 (0.870‐10.571)   0.082
  Tumor location (Right/Left)                        0.747 (0.516‐1.080)     0.121                                          
  Clinical stage (\>II/≤II)                          1.885 (1.284‐2.767)     0.001                   1.201 (0.655‐2.203)    0.553
  Menopause status (\>12/≤12 mo since LMP)           1.812 (1.149‐2.859)     0.011                   1.530 (0.784‐2.986)    0.213
  Neoplasm status (With tumor/Tumor‐free)            6.814 (4.510‐10.295)    0.000                   7.573 (4.465‐12.845)   0.000

TCGA, The Cancer Genome Atlas.

John Wiley & Sons, Ltd

![Kaplan‐Meier survival analysis for all patients with breast cancer in TCGA set according to the model stratified by significantly clinicopathological risk factors. A‐B, Patients' age. C‐D, CNA. E‐F, Neoplasm status. *P*‐values were calculated by the log‐rank test. CNA: copy number aberration; HR: hazard ratio](CAM4-8-593-g003){#cam41962-fig-0003}

3.4. The three‐mRNA model had strongly diagnostic power in the prognostic prediction {#cam41962-sec-0016}
------------------------------------------------------------------------------------

To verify its strongly predictive power in prognosis, we calculated the area under the curve (AUC) value at 5 years with the time‐dependent ROC analysis among the significant clinical factors, three mRNAs, and this new model. We found that AUC value (0.684 (0.586‐0.782)) of this model was much higher than any single AUC value from the three clinical factors (0.597 (0.499‐0.695) for age, 0.592 (0.494‐0.690) for CNA, 0.619 (0.521‐0.717) for neoplasm status; Figure [4](#cam41962-fig-0004){ref-type="fig"}A) and the three mRNAs (0.532 (0.434‐0.630) for *TBX21*, 0.563 (0.465‐0.661) for *TGIF2*, 0.536 (0.438‐0.634) for *CYCS*; Figure [4](#cam41962-fig-0004){ref-type="fig"}B), which was validated in the testing set (n = 703) integrated by another 4 independent datasets (Figure [4](#cam41962-fig-0004){ref-type="fig"}C), although not all results reached statistically significant. These data indicated that the model was not only much higher prognostic accuracy than any other clinicopathological risk factors or single mRNA alone, but also added diagnostic power to clinicopathological prognostic features.

![Time‐dependent ROC curves compare the prognostic accuracy of the model with clinicopathological risk factors and single mRNA in patients from the training set and all testing tests. (A) Comparison of the prognostic accuracy by the model (high vs low risk), Age (≤60 y vs \>60 y), CNA (≤0.251 vs \>0.251), neoplasm status (with tumor vs tumor‐free), combined clinical prognostic factors alone, or the classifier and clinicopathological prognostic factors combined. (B‐C) Comparisons of the prognostic accuracy by the model (high vs low risk), and *TBX21* (low vs high expression), *TGIF2* (low vs high expression), or *CYCS*(high vs low expression) in the training set (B) and the testing set (C). *P*‐values show the AUC at 5 y for the model vs the AUC at 5 y for other features. ROC: receiver operator characteristic; AUC: area under curve; CI: confidence interval; CNA: copy number aberration](CAM4-8-593-g004){#cam41962-fig-0004}

3.5. The three‐mRNA model improved the survival identification between metastatic and nonmetastatic breast cancers {#cam41962-sec-0017}
------------------------------------------------------------------------------------------------------------------

To investigate whether the model was clinically associated with the metastasis, a special analysis of the three mRNAs was conducted between two groups with or without metastasis in TCGA set. As a result, we noted that the survival status was not identified between breast cancers with or without metastasis (HR = 1.503 (0.936‐2.415), *P* = 0.092; Figure [5](#cam41962-fig-0005){ref-type="fig"}A,C). Results from another subset analysis using our model showed that patients in the low‐risk group had a significantly favorable clinical outcome in nonmetastatic group compared with the metastatic one (HR = 1.803 (1.075‐3.024), *P = *0.025; Figure [5](#cam41962-fig-0005){ref-type="fig"}A,C), or in patients with any poor prognostic features (HR = 1.487 (1.025‐2.156), *P = *0.037; Figure [5](#cam41962-fig-0005){ref-type="fig"}B,C). Furthermore, patients with both low‐risk scores and any poor prognostic factors had a much better survival benefit from nonmetastatic status (HR = 1.740 (1.028‐2.945), *P = *0.039; Figure [5](#cam41962-fig-0005){ref-type="fig"}B,C). The results above indicated that the model could successfully improve the survival identification between breast cancer patients with or without metastasis.

![Effect of metastasis in different subgroups. A‐B, Kaplan‐Meier survival curves for patients in different subgroups stratified by the metastatic status. C, Effect of metastatic status on OS in different subgroups](CAM4-8-593-g005){#cam41962-fig-0005}

3.6. The three‐mRNA model predicted the survival probability precisely by integrating other clinicopathological risk factors {#cam41962-sec-0018}
----------------------------------------------------------------------------------------------------------------------------

To explore a quantitative method for calculating precise probability of cancer recurrence with or without metastasis, we developed two nomograms---metastasis and nonmetastasis---that integrated both the model and another three significant clinical risk factors (Figure [6](#cam41962-fig-0006){ref-type="fig"}A). Calibration plots displayed that C‐index of nonmetastasis nomogram (0.844 ± 0.063, *P* = 0.000) was similar with that of metastasis nomogram (0.802 ± 0.065, *P* = 0.000), which indicated that the nomograms worked well compared with an ideal model (Figure [6](#cam41962-fig-0006){ref-type="fig"}B). Further validation was performed when we applied bootstrap cross‐validation algorithm into the patients from TCGA set. The integrated Brier Score for Cox bootstrap of metastasis (0.069) was less than out of bag (OOB) of metastasis (0.109) at the range of integration (0, 126) months, which was similar with the result from nonmetastasis status (Figure [6](#cam41962-fig-0006){ref-type="fig"}C). Meanwhile, the AUC values of nonmetastatic and metastatic nomogram were 0.656 (0.552‐0.760) and 0.628 (0.528‐0.728), respectively (Figure [S3](#cam41962-sup-0003){ref-type="supplementary-material"}). Generally, these nomograms could predict the survival probability accurately in patients with breast cancer as a practical clinical tool.

![Nonmetastasis and metastasis nomograms to predict risk of cancer recurrence without or with metastasis in patients with breast cancer. A, Un‐metastasis and metastasis nomograms for predicting proportion of breast cancer patients with OS, either without (left) or with (right) metastasis status. B, Plots display the calibration of two models in terms of agreement between predicted and observed 5‐year survivals. The plot shows the model performance, relative to the 45‐degree line, which embodies perfect prediction. C, Validation of the predictive power of the nomograms' model by bootstrap cross‐validation method. CNA, copy number aberration; OOB, out of bag; OS, overall survival; SD, standard deviation](CAM4-8-593-g006){#cam41962-fig-0006}

4. DISCUSSION {#cam41962-sec-0019}
=============

In the past few years, the study correlated with mRNAs in breast cancer progress was increased inch by inch.[23](#cam41962-bib-0023){ref-type="ref"}, [24](#cam41962-bib-0024){ref-type="ref"}, [25](#cam41962-bib-0025){ref-type="ref"} However, little has been reported for the inflammation‐related genes to predict breast cancer survival in a large dataset. Here, a three‐mRNA model was developed as a markedly predictor of survival in breast cancer patients with little overlap with the others. To reduce the predictive error rates, the random sampling and ensemble strategies were used in RSF algorithm and Cox regression method. And then, the measures of genes importance were performed by RSF algorithm to result in remarkable performance in factors screening. Next, a model was constructed with three mRNAs by Cox regression method. We espoused that the prognostic value could be substantially improved by integrating multiple biomarkers into a single model.[26](#cam41962-bib-0026){ref-type="ref"} However, it would be greater to have fewer genes as possible to produce the new model more competitive. Through the RSF analysis, the three‐mRNA signature was necessary to develop the final model. And the result validated it as the "less‐gene‐possible" combination could subclassify the breast cancer risk status effectively.

To identify survival of the three‐mRNA model of either metastatic or nonmetastatic breast cancers on principle of "less‐gene‐possible" combination, we select one published model including two genes (HOXB13 and IL17BR) reported by Ma et al[27](#cam41962-bib-0027){ref-type="ref"} to compare the predictive power of prognosis in breast cancer patients from the TCGA dataset. By using ROC analysis, we found that AUC value of the three‐mRNA model was higher than the two‐gene model in the metastatic group (0.630 vs 0.541, Figure [S3](#cam41962-sup-0003){ref-type="supplementary-material"}A) and nonmetastatic group (0.650 vs 0.501, Figure [S3](#cam41962-sup-0003){ref-type="supplementary-material"}B) of breast cancer patients. The data suggested that our three‐mRNA model has more strongly diagnostic power for predicting the clinical outcome in breast cancers.

To further verify the independence of this model in prediction, we assessed the correlation between this model and the basic clinical factors and identified three factors (age, CNA, and neoplasm status) as dramatically candidate predictive variables in training set. Then, we performed a multivariate Cox regression analysis and discovered this model as an independent factor. Especially the model could stratify patients with poor or favorable survival in the same age, CNA, or neoplasm status stratum, which demonstrated that the potential application of this model in adding diagnostic power to the combined clinicopathological factors. Because the positive metastasis status negatively influenced the prognosis of patients with breast cancer,[28](#cam41962-bib-0028){ref-type="ref"} the predictive value of this model discovered in TCGA set furtherly verify its remarkable association with metastasis. The nomograms developed by the model and another three significant risk factors produced a quantitative tool for predicting survival of patients. These results verified again that this model could divide the patients into high‐ and low‐risk group more effectively and precisely than the performance of any other single mRNA or clinical factor.

Interestingly, we discovered the important tradeoffs with respect to the application of the three‐mRNA model in breast cancer patients who were deemed to be at high or low risk of recurrence based on the clinical and pathological factors. Also, we could report the median survival time, 3/5/10‐year OS probability for these patients with or without metastasis by adding the three‐mRNA model into the nomogram. Overall, we could identify 40% and 60% in breast cancer patients with or without metastasis as especially short survival by evaluating individuals who had low‐ or high‐risk scores along with the basal clinical characteristics. This study gives us a big hint that we should pay enough attention to these patients in clinical treatment.

Importantly, it remains unknown whether this model has similar predictive power beyond molecular subtypes in breast cancer patients from different hospitals in China as this predictive model was derived from the TCGA set. Another limitation of this research is that the validity of this model should be further confirmed in the prospect cohorts, especially for the correlation with tumor size. In addition, the possible function of this signature in breast cancer could be deduced by performing functional enrichment analysis on GO terms and KEGG pathways (Figure [S5](#cam41962-sup-0005){ref-type="supplementary-material"}). It is a plausible inference from the result that this signature might be involved in cell apoptotic process and differentiation, energy metabolism, and pathways in cancer. However, these discoveries should be verified by bio‐experimentation.

Generally, our study identified three mRNAs (*TBX21*, *TGIF2,* and *CYCS*) that were significantly altered between high‐ and low‐risk patients with breast cancer. The three‐mRNA model was independent and predicted the prognosis of patients robustly. Furthermore, this model could predict survival probability precisely in patients with or without metastasis. And it is the first predictive model developed by inflammation‐related mRNA signature to evaluate survival of patients with breast cancer.
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